A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines

Alejandro M. Gomez, George (Giorgi) Babuadze, Marc André Plourde-Campagna, Hiva Azizi, Alice Berger, Robert Kozak, Marc Antoine de La Vega, Ara Xiii, Maedeh Naghibosadat, Marie Edith Nepveu-Traversy, Jean Ruel, Gary P. Kobinger

Research output: Contribution to journalArticlepeer-review


In recent years, tattooing technology has shown promising results toward evaluating vaccines in both animal models and humans. However, this technology has some limitations due to variability of experimental evaluations or operator procedures. The current study evaluated a device (intradermal oscillating needle array injection device: IONAID) capable of microinjecting a controlled dose of any aqueous vaccine into the intradermal space. IONAID-mediated administration of a DNA-based vaccine encoding the glycoprotein (GP) from the Ebola virus resulted in superior T- and B-cell responses with IONAID when compared to single intramuscular (IM) or intradermal (ID) injection in mice. Moreover, humoral immune responses, induced after IONAID vaccination, were significantly higher to those obtained with traditional passive DNA tattooing in guinea pigs and rabbits. This device was well tolerated and safe during HIV vaccine delivery in non-human primates (NHPs), while inducing robust immune responses. In summary, this study shows that the IONAID device improves vaccine performance, which could be beneficial to the animal and human health, and importantly, provide a dose-sparing approach (e.g., monkeypox vaccine).

Original languageEnglish (US)
Article number172
Journalnpj Vaccines
Issue number1
StatePublished - Dec 2022

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'A novel intradermal tattoo-based injection device enhances the immunogenicity of plasmid DNA vaccines'. Together they form a unique fingerprint.

Cite this